Spots Global Cancer Trial Database for A Trial of Amrubicin and Carboplatin With Pegfilgrastim in Patients With Extensive-Stage Small Cell Lung Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Trial of Amrubicin and Carboplatin With Pegfilgrastim in Patients With Extensive-Stage Small Cell Lung Cancer
Official Title: A Phase II Trial of Amrubicin and Carboplatin With Pegfilgrastim in Patients With Extensive-Stage Small Cell Lung Cancer
Study ID: NCT01076504
Conditions
Study Description
Brief Summary: This proposed trial will investigate the combination of amrubicin and carboplatin in the first-line treatment of patients with extensive-stage small cell lung cancer (ES- SCLC). Since myelosuppression is the most common toxicity produced by this drug combination, pegfilgrastim will be administered with each treatment cycle. This trial will be the first clinical trial to evaluate a combination of amrubicin and carboplatin in the first-line treatment of ES SCLC in a U.S. population.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Northeast Arkansas Clinic, Jonesboro, Arkansas, United States
Florida Cancer Specialists, Fort Myers, Florida, United States
Watson Clinic Center for Cancer Care and Research, Lakeland, Florida, United States
Florida Hospital Cancer Institute, Orlando, Florida, United States
Medical Oncology Associates of Augusta, Augusta, Georgia, United States
Baptist Hospital East, Louisville, Kentucky, United States
Norton Cancer Institute, Louisville, Kentucky, United States
Hematology Oncology Clinic, LLP, Baton Rouge, Louisiana, United States
Center for Cancer and Blood Disorders, Bethesda, Maryland, United States
National Capital Clinical Research Consortium, Bethesda, Maryland, United States
Grand Rapids Clinical Oncology Program, Grand Rapids, Michigan, United States
Research Medical Center, Kansas City, Missouri, United States
Nebraska Methodist Cancer Center, Omaha, Nebraska, United States
Oncology Hematology Care, Cincinnati, Ohio, United States
South Carolina Oncology Associates, PA, Columbia, South Carolina, United States
Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, United States
Family Cancer Center, Collierville, Tennessee, United States
Tennessee Oncology, PLLC, Nashville, Tennessee, United States
Peninsula Cancer Institute, Newport News, Virginia, United States
Virginia Cancer Institute, Richmond, Virginia, United States
Contact Details
Name: David R Spigel, M.D.
Affiliation: SCRI Development Innovations, LLC
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
